Castle Biosciences Inc (CSTL) concluded trading on Thursday at a closing price of $21.51, with 0.45 million shares of worth about $9.77 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -35.75% during that period and on April 17, 2025 the price saw a gain of about 1.18%. Currently the company’s common shares owned by public are about 28.48M shares, out of which, 27.97M shares are available for trading.
Stock saw a price change of 11.45% in past 5 days and over the past one month there was a price change of 4.72%. Year-to-date (YTD), CSTL shares are showing a performance of -19.29% which increased to 13.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $16.97 but also hit the highest price of $35.84 during that period. The average intraday trading volume for Castle Biosciences Inc shares is 408.24K. The stock is currently trading 7.36% above its 20-day simple moving average (SMA20), while that difference is down -2.84% for SMA50 and it goes to -18.84% lower than SMA200.
Castle Biosciences Inc (NASDAQ: CSTL) currently have 28.48M outstanding shares and institutions hold larger chunk of about 98.53% of that.
The stock has a current market capitalization of $620.45M and its 3Y-monthly beta is at 1.12. PE ratio of stock for trailing 12 months is 35.10, while it has posted earnings per share of $0.61 in the same period. It has Quick Ratio of 7.13 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CSTL, volatility over the week remained 4.68% while standing at 5.63% over the month.
Analysts are in expectations that Castle Biosciences Inc (CSTL) stock would likely to be making an EPS of -0.07 in the current quarter, while forecast for next quarter EPS is -0.37 and it is -1.79 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.31 which is 0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.09 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -349.91% while it is estimated to decrease by -16.60% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Guggenheim on December 14, 2023 offering a Buy rating for the stock and assigned a target price of $25 to it. Coverage by Scotiabank stated Castle Biosciences Inc (CSTL) stock as a Sector outperform in their note to investors on January 05, 2023, suggesting a price target of $54 for the stock. On January 07, 2022, Stephens Initiated their recommendations, while on April 30, 2021, Lake Street Initiated their ratings for the stock with a price target of $94. Stock get an Overweight rating from KeyBanc Capital Markets on November 10, 2020.
